Doripenem is a carbapenem with a broad spectrum of activity. It inhibits bacterial cell wall biosynthesis and is indicated for the treatment of serious infections in secondary care.
Doripenem is given by infusion over one to four hours every eight hours. The longer infusion period should be considered when the infection is caused by less susceptible pathogens; extending the infusion time maximises the period when the plasma concentration exceeds the minimum inhibitory concentration.
Species resistant to other carbapenems do generally express co-resistance to doripenem.
Further information: Janssen-Cilag